THE-NAGA-GROUP-AG
1.4.2021 13:16:04 CEST | Business Wire | Press release
The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports its preliminary unaudited results of the first quarter 2021.
Unaudited group sales jumped by 69% to USD 13.7 million (Q1 2020: USD 8.1 million), whilst the number of real-money transactions jumped by 141% to 2.9 million (Q1 2020: 1.2 million). Traded volume crossed USD 70 billion, an increase of 155% (Q1 2020: USD 27 billion). Signups jumped by 480% to 93,000 in Q1 2021 compared to 16,000 account signups in Q1 2020 which resulted in another important milestone for NAGA crossing 1 million registered accounts to date. Another highlight is the growth in transactions of NAGAs unique auto-copy tool. More than 1.4 million trades were copied trades on the NAGA platform, which is an increase of more than 475% compared to 0.27 million copied trades in Q1 2020.
"We are pleased with our Q1 results and especially with the growth metrics. We see three-digit growth across our core metrics. Since the restructuring in 2019 we have delivered growth for the 9th consecutive quarter with Q1 2021 being the strongest in our entire company history. It confirms that 2020 was just the beginning of our growth story. Our social trading business is growing very strongly, and we are clearly expanding our competitive advantage underlining our FinTech and user-experience focused character. Compared to classical brokerage funnels our NAGA-Autocopy drives 150% more in user activity and dramatically improved our conversion rates, reduced acquisition cost metrics and improved churn metrics", comments NAGA CEO Benjamin Bilski.
According to various research outlets, the amount of people joining the stock markets is gaining momentum and will continue to grow strongly. Given NAGAs median client age of 34 and 80% of the transactions taking place on a mobile device, it is a clear confirmation that users appreciate mobile, easy-to-use and community-driven investing platforms that allow them to manage their money independently and invest across all asset classes including digital assets such as Bitcoin. For further diversification, the company plans to open a new local office in Vietnam and actively prepares the entry into the Australian market.
"We are on track to hit our annual targets. We will continue to scale marketing and further optimize our acquisition funnels. Comparing growth and further potential to our competition, but also private FinTech companies, we are very confident about our future upside. Given the shift of user demands and the positive feedback we are receiving about our unique platform, we will announce major exciting product updates in the upcoming quarters to strengthen our position as social neo-broker and investing platform", adds Bilski.
NAGA is also pleased to announce that it has filed an application with OTC Markets Group for the Company's shares to be cross traded publicly on the OTCQX Venture Market which would make NAGA shares more widely available to North American investors. Trading on the US OTCQX market would have no impact on existing NAGA's ordinary shares and no new ordinary shares will be issued as part of the cross-trade. NAGA will continue to rely on the announcements and disclosures it makes to Scale and will have no SEC reporting requirements. Should the application be successful, the cross-trading facility will be provided through OTC Markets Group Inc., located in New York, USA. OTC Markets operates the world's largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-traded companies.
"We would like to make NAGA Group AG available to US markets in order to gain access to a broader investor base and enhance our visibility in North America. Cross trading on OTC Markets represents an important development for the company", adds Bilski.
Furthermore, NAGA reports that the convertible bonds with a nominal value of EUR 8 million, as announced in the ad hoc announcement of March 8, 2021, have been placed in full.
###
About NAGA
NAGA is an innovative fintech company that seamlessly connects personal finance transactions and investments through its social trading platform. The company's proprietary platform offers a range of products from stock trading, investments and cryptocurrencies to a physical Mastercard. Additionally, the platform allows for exchanges with other traders, provides relevant information in the feed, and autocopy features for successful members' trades. NAGA is a synergistic total solution that is easily accessible and inclusive. It provides an improved foundation to trade, invest, network, earn and pay. This applies to both fiat and crypto products.
| Language: | English |
| Company: | The NAGA Group AG |
| Hohe Bleichen 12 | |
| 20354 Hamburg | |
| Germany | |
| Email: | info@naga.com |
| Internet | www.naga.com |
| ISIN: | DE000A161NR7 |
| WKN: | A161NR |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, |
| Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005406/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom